Specifically, sorafenib is able to inhibit tyrosine kinases of the VEGF signaling pathway to reduce tumor angiogenesis and RAF kinase, associated with an inhibition of the MAPK/ERK pathway leading to reduced cell proliferation [20]. The gene discussed is VEGFA; the disease is neoplasm.